The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome
Open accessAbstract
BACKGROUND: After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse. METHODS: We conducted a multicenter, randomized trial that compared fluconazole (200 mg per day given orally) with amphotericin B (1 mg per kilogram of body weight per week given intravenously) in patients with AIDS who had completed primary therapy for cryptococcal meningitis with amphotericin B (greater than or equal to 15 mg per kilogram). To be eligible, patients had to have at least two negative cultures of cerebrospinal fluid immediately before randomization. The primary end point was relapse of cryptococcal disease as confirmed by biopsy or culture. RESULTS: Of 218 patients initially enrolled, 119 were assigned to fluconazole and 99 to amphotericin B. Twenty-three patients were found not to have met the entry criteria; six other patients assigned to amphotericin B did not receive it and were lost to follow-up. Of the remaining 189 patients, after a median follow-up of 286 days 14 of 78 receiving amphotericin B (18 percent) and 2 of 111 assigned to fluconazole (2 percent) had relapses of symptomatic cryptococcal disease (P less than 0.001 by Fisher's exact test). There was a difference of 19 percent in the estimated probability of remaining relapse-free at one year between the fluconazole group (97 percent) and the amphotericin B group (78 percent) (95 percent confidence interval, 7 percent to 31 percent; P less than 0.001). Serious drug-related toxicity was more frequent in the amphotericin B group (P = 0.02), as were bacterial infections (P = 0.004) and bacteremia (P = 0.002). CONCLUSIONS: Fluconazole taken by mouth is superior to weekly intravenous therapy with amphotericin B to prevent relapse in patients with AIDS-associated cryptococcal meningitis after primary treatment with amphotericin B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Snedecor, G. W., & Cochran, W. G. (1967) · Cited by 6,573
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
“Proving the null hypothesis” in clinical trials
Blackwelder, W. C. (1982) · Controlled Clinical Trials · doi:10.1016/0197-2456(82)90024-1 · Cited by 887
Infections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome
Chuck, S. L., & Sande, M. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211205 · Cited by 797
Cryptococcosis in the Acquired Immunodeficiency Syndrome
KOVACS, J. A., KOVACS, A. A., POLIS, M., WRIGHT, W. C., GILL, V. J., TUAZON, C. U., GELMANN, E. P., LANE, H. C., LONGFIELD, R., OVERTURF, G., et al. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-533 · Cited by 621
Self-citationZUGER, A., LOUIE, E., HOLZMAN, R. S., SIMBERKOFF, M. S., & RAHAL, J. J. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-2-234 · Cited by 522
Cryptococcal Meningitis in Patients with AIDS
Dismukes, W. E. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.4.624 · Cited by 389
Self-citationBozzette, S. A., Larsen, R. A., Chiu, J., Leal, M. A. E., Jacobsen, J., Rothman, P., Robinson, P., Gilbert, G., McCutchan, J. A., Tilles, J., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102283240902 · Cited by 301
Self-citation
Cited by
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
Mitchell, T. G., & Perfect, J. R. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.515 · Cited by 1,213
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Practice Guidelines for the Management of Cryptococcal Disease
Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E., & Mycoses Study Group Cryptococcal Subproject (2000) · Clinical Infectious Diseases · doi:10.1086/313757 · Cited by 1,105
Self-citationMasur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
Metadata
- Authors
- Powderly, W. G., Saag, M. S., Cloud, G. A., Robinson, P., Meyer, R. D., Jacobson, J. M., Graybill, J. R., Sugar, A. M., McAuliffe, V. J., Follansbee, S. E., Tuazon, C. U., Stern, J. J., Feinberg, J., Hafner, R., Dismukes, W. E., the NIAID AIDS Clinical Trials Group, & the NIAID Mycoses Study Group*
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-03-19
- Volume
- 326
- Issue
- 12
- Pages
- 793-798
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2316588957
- Cited by
- 353
- References
- 16
- FWCI
- 28.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome. https://app.cochat.ai/papers/10.1056/nejm199203193261203
- The paper
- Powderly, W. G., Saag, M. S., Cloud, G. A., Robinson, P., Meyer, R. D., Jacobson, J. M., Graybill, J. R., Sugar, A. M., McAuliffe, V. J., Follansbee, S. E., Tuazon, C. U., Stern, J. J., Feinberg, J., Hafner, R., Dismukes, W. E., the NIAID AIDS Clinical Trials Group, & the NIAID Mycoses Study Group*. (1992). A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine. https://doi.org/10.1056/nejm199203193261203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.